Overview

A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants

Status:
NOT_YET_RECRUITING

Trial end date:
2026-04-16

Target enrollment:

Participant gender:

Summary

This two-part study will evaluate the bioequivalence, safety, and tolerability of a single SC dose of trastuzumab administered via handheld syringe/syringe pump (HHS/SP) with infusion set (IS) and an on-body delivery system (OBDS).

Phase:

PHASE1

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Trastuzumab